The estimated Net Worth of Heek Christi Van is at least $338 Thousand dollars as of 6 June 2022. Ms. Van owns over 10,526 units of Concert Pharmaceuticals Inc stock worth over $214,699 and over the last 8 years she sold CNCE stock worth over $0. In addition, she makes $122,941 as Independent Director at Concert Pharmaceuticals Inc.
Christine has made over 2 trades of the Concert Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 10,526 units of CNCE stock worth $49,999 on 6 June 2022.
The largest trade she's ever made was buying 10,526 units of Concert Pharmaceuticals Inc stock on 6 June 2022 worth over $49,999. On average, Christine trades about 2,053 units every 104 days since 2016. As of 6 June 2022 she still owns at least 25,651 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Ms. Van stock trades at the bottom of the page.
Christine van Heek is an Independent Director of Concert Pharmaceuticals Inc. Ms. van Heek has served as a member of our Board since April 2016. Ms. van Heek has served as an adviser and consultant to several companies in the biopharmaceutical industry. From 1991 to 2003, Ms. van Heek served in various roles at Genzyme Corporation, a biotechnology company, including as Corporate Officer and President, Therapeutics Division; General Manager, Renal Division; and Vice President, Global Marketing. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA. Ms. van Heek received a B.S.N. from the University of Iowa and an M.B.A. from Lindenwood University in St. Louis.
As the Independent Director of Concert Pharmaceuticals Inc, the total compensation of Christine Heek at Concert Pharmaceuticals Inc is $122,941. There are 11 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.
Christine Heek is 63, she's been the Independent Director of Concert Pharmaceuticals Inc since 2016. There are 5 older and 9 younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.
Heek's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: